Jason Francis Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jason Francis Lee has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- David Z. I. Cherney
Division of Nephrology, Department of Medicine, University Health Network, Toronto, Ontario, Canada
2 shared publications - Alanna Weisman
Lunenfeld‐Tanenbaum Research Institute Mount Sinai Hospital Toronto Ontario Canada
1 shared publication - Atit Dharia
Department of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, Toronto, Ont
1 shared publication - Ayodele Odutayo
Division of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
1 shared publication Christine Nash
Department of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, Toronto, Ont
1 shared publicationEcaterina Berzan
Toronto General Hospital Research Institute, University Health Network, ON, Canada
1 shared publication
Latest Publications
- 3 April 2023
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 59 (3) , 245-251
Diabetic retinopathy screening integrated in a multidisciplinary diabetes care clinic: a pilot project
- 3 April 2023
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 59 (3) , 245-251
Diabetic retinopathy screening integrated in a multidisciplinary diabetes care clinic: a pilot project
- Open Access
- 30 April 2021
- Published by Korean Endocrine Society in Endocrinology and Metabolism
- Vol. 36 (2) , 256-269
Cardiorenal Protection in Diabetic Kidney Disease
Over the last 5 years there have been many new developments in the management of diabetic kidney disease. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 (SGLT2) inhibitors were initially used for glycemic control, but more recent studies have now shown that their benefits extend to cardiovascular and kidney outcomes. The recent addition of data on the novel mineralocorticoid receptor antagonist (MRA) gives us another approach to further decrease the residual risk of diabetic kidney disease progression. In this review we describe the mechanism of action, key studies, and possible adverse effects related to these three classes of medications. The management of type 2 diabetes now includes an increasing number of medications for the management of comorbidities in a patient population at significant risk of cardiovascular disease and progression of chronic kidney disease. It is from this perspective that we seek to outline the rationale for the sequential and/or combined use of SGLT2 inhibitors, GLP-1 RA and MRAs in patients with type 2 diabetes for heart and kidney protection.
- 30 April 2021
- Published by Korean Endocrine Society in Endocrinology and Metabolism
- Vol. 36 (2) , 256-269
Open AccessCardiorenal Protection in Diabetic Kidney Disease
Over the last 5 years there have been many new developments in the management of diabetic kidney disease. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 (SGLT2) inhibitors were initially used for glycemic control, but more recent studies have now shown that their benefits extend to cardiovascular and kidney outcomes. The recent addition of data on the novel mineralocorticoid receptor antagonist (MRA) gives us another approach to further decrease the residual risk of diabetic kidney disease progression. In this review we describe the mechanism of action, key studies, and possible adverse effects related to these three classes of medications. The management of type 2 diabetes now includes an increasing number of medications for the management of comorbidities in a patient population at significant risk of cardiovascular disease and progression of chronic kidney disease. It is from this perspective that we seek to outline the rationale for the sequential and/or combined use of SGLT2 inhibitors, GLP-1 RA and MRAs in patients with type 2 diabetes for heart and kidney protection.